ClinicalTrials.gg
Not yet recruitingNCT07934589ECO-IAUpdated Nov 13, 2026

Artificial Intelligence-assisted Ultrasound Diagnosis of Musculoskeletal Injuries.

An observational study in Artifical Intelligence and Physiotherapy Specialty, sponsored by Universidad Pontificia de Salamanca. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Universidad Pontificia de Salamanca · Observational

How we know

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The proposal combines clinical research in physiotherapy, traumatology and orthopaedics with artificial intelligence, computer vision and health-data science.

Read the detailed description

ECO-IA is submitted as an individual research project under the "Non-oriented research" modality. The project addresses a relevant gap in clinical musculoskeletal care: ultrasound is widely available, safe, radiation-free and useful for the assessment of tendons, muscles, ligaments and joints, but its diagnostic value depends strongly on operator training, image-acquisition protocol and interpretative experience.

The proposal combines clinical research in physiotherapy, traumatology and orthopaedics with artificial intelligence, computer vision and health-data science. It aims to develop, validate and prepare for clinical translation an AI-based decision-support system capable of assisting healthcare professionals in the identification and characterisation of common musculoskeletal injuries from ultrasound images. This is consistent with the purpose of the call: generating new knowledge while creating opportunities for predoctoral research training.

02

Conditions studied

  • Artifical Intelligence
  • Physiotherapy Specialty
03

In context

Lead sponsor

Universidad Pontificia de Salamanca is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with musculoskeletal pain affecting tendons, muscles, ligaments or bursae

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with musculoskeletal pain affecting tendons, muscles, ligaments or bursae

Exclusion criteria

Exclusion Criteria:

  • Patients with severe, acute pain consistent with an open fracture; surgical procedures in the area under examination and diagnosis. Uncooperative patients who do not sign the form.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • IA Group

    Diagnosis by IA

  • Medical Expert Group

    Diagnosis by a medical expert

06

What researchers measure

Primary outcomes

  1. Diagnostic imaging

    Ability to carry out a medical diagnosis based on imaging findings

    Time frame: 1 day

07

Study locations

1 site
08

References and documents

Publications

  • Humphries MP, Kaye D, Stankeviciute G, Halliwell J, Wright AI, Bansal D, Brettle D, Treanor D. Development of a multi-scanner facility for data acquisition for digital pathology artificial intelligence. J Pathol. 2024 Sep;264(1):80-89. doi: 10.1002/path.6326. Epub 2024 Jul 10. PubMed 38984400 ↗
  • Berezowska S, Cathomas G, Grobholz R, Henkel M, Jochum W, Koelzer VH, Kreutzfeldt M, Mertz KD, Rossle M, Soldini D, Zlobec I, Janowczyk A. Digital image analysis and artificial intelligence in pathology diagnostics-the Swiss view. Pathologie (Heidelb). 2023 Dec;44(Suppl 3):222-224. doi: 10.1007/s00292-023-01262-w. Epub 2023 Nov 21. PubMed 37987817 ↗
  • Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. Diagn Pathol. 2023 Oct 3;18(1):109. doi: 10.1186/s13000-023-01375-z. PubMed 37784122 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2027; primary completion for Jan 2028, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 13, 2026
StartEst.
Nov 25, 2027
Primary completionEst.
Jan 10, 2028
CompletionEst.
Dec 15, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934589
Lead sponsor
Universidad Pontificia de Salamanca
Responsible party
Jorge Velazquez (Principal Investigator, Universidad Pontificia de Salamanca) — Principal investigator
First posted
Nov 13, 2026
Start date
Nov 25, 2027 (estimated)
Primary completion
Jan 10, 2028 (estimated)
Completion
Dec 15, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

JORGE VELÁZQUEZ SAORNIL, PhD.
Contact
jvelazquezsa@upsa.es
923277100
Jorge Velázquez, PhD.
Contact
jvelazquezsa@upsa.es
Jorge Velázquez Saornil, Principal investigator
principal investigator · Universidad Pontíficia de Salamanca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion